These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 31057111

  • 1. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
    Aghdashi MA, Khadir M, Dinparasti-Saleh R.
    Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
    [Abstract] [Full Text] [Related]

  • 2. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [Abstract] [Full Text] [Related]

  • 3. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 12. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 13. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.
    Takase K, Horton SC, Ganesha A, Das S, McHugh A, Emery P, Savic S, Buch MH.
    Ann Rheum Dis; 2014 Sep; 73(9):1695-9. PubMed ID: 24854356
    [Abstract] [Full Text] [Related]

  • 16. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, Zingarelli S, Caporali R, Cattaneo R, Montecucco CM.
    Clin Exp Rheumatol; 2007 Sep; 25(5):676-83. PubMed ID: 18078613
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].
    Cavazzana I, Franceschini F, Danieli E, Frassi M, Vianelli M, Gorla R, Airò P, Cattaneo R.
    Reumatismo; 2005 Dec; 57(4):267-72. PubMed ID: 16380754
    [Abstract] [Full Text] [Related]

  • 19. Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results.
    Caramaschi P, Ruzzenente O, Pieropan S, Volpe A, Carletto A, Bambara LM, Biasi D.
    Rheumatol Int; 2007 May; 27(7):649-54. PubMed ID: 17136355
    [Abstract] [Full Text] [Related]

  • 20. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.
    Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA.
    Arthritis Res Ther; 2014 Jun 17; 16(3):R125. PubMed ID: 24938855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.